RT Journal Article
SR Electronic
T1 Global estimates of the fitness advantage of SARS-CoV-2 variant Omicron
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.15.22276436
DO 10.1101/2022.06.15.22276436
A1 van Dorp, Christiaan
A1 Goldberg, Emma
A1 Ke, Ruian
A1 Hengartner, Nick
A1 Romero-Severson, Ethan
YR 2022
UL http://medrxiv.org/content/early/2022/06/16/2022.06.15.22276436.abstract
AB New variants of SARS-CoV-2 show remarkable heterogeneity in their relative fitness both over time and space. In this paper we extend a previously published model for estimating the selection strength for new SARS-CoV-2 variants to a hierarchical, mixed-effects, renewal equation model. This formulation allows us to globally estimate selection effects at different spatial levels while controlling for complex patterns of transmission and jointly inferring the effects of unit-level covariates in the spatial heterogeneity of SARS-CoV-2 selection effects. Applying this model to the spread of Omicron in 40 counties finding evidence for very strong (64%) but very heterogeneous selection effects at the country level. We further considered different measures of vaccination levels and measures of recent population-level infection as possible explanations. However, none of those variables were found to explain a significant proportion of the heterogeneity in country-level selection effects. We did find a significant positive correlation between the selection advantage of Delta and Omicron at the country level, suggesting that region-specific explanatory variables of fitness differences do exist. Our method is implemented in the Stan programming language, can be run on standard commercial-grade computing resources, and should be straightforward to apply to future variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch presented in this article was supported by the Laboratory Directed Research and Development program of Los Alamos National Laboratory under project number 20210887ER. CHvD was funded by the National Institutes of Health (www.nih.gov), grant number U01 AI150680.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used (or will use) ONLY openly available human data that were originally located at: http://www.gisaid.org/ https://ourworldindata.org/coronavirus https://github.com/CSSEGISandData/COVID-19I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the present study are available online at http://www.gisaid.org/ https://ourworldindata.org/coronavirus and https://github.com/CSSEGISandData/COVID-19 https://github.com/eeg-lanl/sarscov2-selection